Japanese nationwide post-marketing survey of S-1 in patients with advanced gastric cancer
Data up to Jan 2025
Total Citations Per Year
Abstract
References (6)
Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1M tegafur–0.4M gimestat–1M otastat potassium) in advanced gastric cancer patients
1998 • 565 citations
Phase II Study of S-1, a Novel Oral Derivative of 5-Fluorouracil, in Advanced Gastric Cancer
2000 • 437 citations
Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats.
1996 • 372 citations
Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts.
1987 • 262 citations
Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug.
1999 • 224 citations
Clinical trials in Japan
1995 • 14 citations